Literature DB >> 19665924

Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women.

Tasneem Shikary1, David I Bernstein, Yan Jin, Gregory D Zimet, Susan L Rosenthal, Jessica A Kahn.   

Abstract

BACKGROUND: Two HPV vaccines prevent infection with HPV-16 and HPV-18, high-risk (cancer-associated) HPV types which together cause approximately 70% of cervical cancers; one vaccine also prevents HPV-6 and HPV-11, which together cause approximately 90% of anogenital warts. Defining type-specific HPV epidemiology in sexually experienced women will help estimate the potential clinical benefits of vaccinating this population.
OBJECTIVES: To examine HPV epidemiology in a diverse sample of sexually experienced women, and to determine factors associated with high-risk HPV and vaccine-type HPV (HPV-6, HPV-11, HPV-16 and HPV-18). STUDY
DESIGN: Cross-sectional study of 13-26-year-old women (N=409) who completed a questionnaire and provided a cervicovaginal swab. Swabs were genotyped for HPV using PCR amplification. Logistic regression models were used to determine whether participant characteristics, knowledge, and behaviors were associated with high-risk and vaccine-type HPV.
RESULTS: Most women (68.4%) were positive for >or=1 HPV type, 59.5% were positive for >or=1 high-risk type, 33.1% were positive for >or=1 vaccine-type HPV, and 3.5% were positive for both HPV-16 and HPV-18: none was positive for all four vaccine types. In adjusted logistic regression models, Black race (OR 2.03, 95% CI 1.21-3.41) and lifetime number of male sexual partners (OR 4.79, 95% CI 2.04-11.23 for >or=10 partner vs. <or=1 partner) were independently associated with high-risk HPV infection.
CONCLUSIONS: HPV prevalence was very high in this sample of sexually active young women, but <5% were positive for both HPV-16 and HPV-18, suggesting that vaccination could be beneficial for many individual women who are sexually experienced.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665924      PMCID: PMC2767195          DOI: 10.1016/j.jcv.2009.07.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  33 in total

1.  HPV and cervical cancer in the 2007 report.

Authors: 
Journal:  Vaccine       Date:  2007-11-01       Impact factor: 3.641

Review 2.  Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

Authors:  Anna Koulova; Jennifer Tsui; Kathleen Irwin; Pierre Van Damme; Robin Biellik; Maria Teresa Aguado
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

3.  Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States).

Authors:  N Krieger; C Quesenberry; T Peng; P Horn-Ross; S Stewart; S Brown; K Swallen; T Guillermo; D Suh; L Alvarez-Martinez; F Ward
Journal:  Cancer Causes Control       Date:  1999-12       Impact factor: 2.506

4.  Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women.

Authors:  Jessica A Kahn; Susan L Rosenthal; Yan Jin; Bin Huang; Azadeh Namakydoust; Gregory D Zimet
Journal:  Obstet Gynecol       Date:  2008-05       Impact factor: 7.661

5.  Risk of female human papillomavirus acquisition associated with first male sex partner.

Authors:  Rachel L Winer; Qinghua Feng; James P Hughes; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

Review 6.  Age considerations when vaccinating against HPV.

Authors:  Thomas C Wright; Warner K Huh; Bradley J Monk; Jennifer S Smith; Kevin Ault; Thomas J Herzog
Journal:  Gynecol Oncol       Date:  2008-05       Impact factor: 5.482

7.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Authors:  Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

8.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Authors:  Sue J Goldie; Meredith O'Shea; Nicole Gastineau Campos; Mireia Diaz; Steven Sweet; Sun-Young Kim
Journal:  Vaccine       Date:  2008-05-15       Impact factor: 3.641

9.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

10.  Prevalence of human papillomavirus in Indonesia: a population-based study in three regions.

Authors:  J N I Vet; M A de Boer; B E W M van den Akker; B Siregar; S Budiningsih; D Tyasmorowati; S Cornain; A A W Peters; G J Fleuren
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

View more
  16 in total

1.  Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.

Authors:  Jessica A Kahn; Darron R Brown; Lili Ding; Lea E Widdice; Marcia L Shew; Susan Glynn; David I Bernstein
Journal:  Pediatrics       Date:  2012-07-09       Impact factor: 7.124

2.  Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India.

Authors:  Alpana Garg; Vanita Suri; Raje Nijhawan; Neelam Aggarwal; Ritu Aggarwal; Charu Guleria; Mili Thakur
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women.

Authors:  C Smith; L Ding; P M Gorbach; E L Franco; J A Kahn
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-09-21       Impact factor: 1.814

4.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Authors:  Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

5.  Prevalence of the human papillomavirus (HPV) expression of the inner prepuce in asymptomatic boys and men.

Authors:  Gerald Klinglmair; Renate Pichler; Bettina Zelger; Hasan Serkan Dogan; Tanja Becker; Johannes Esterbauer; Markus Riccabona; Wolfgang Loidl; Wolfgang Horninger; Josef Oswald
Journal:  World J Urol       Date:  2012-12-14       Impact factor: 4.226

6.  Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.

Authors:  Dana Whittemore; Lili Ding; Lea E Widdice; Darron A Brown; David I Bernstein; Eduardo L Franco; Jessica A Kahn
Journal:  J Womens Health (Larchmt)       Date:  2016-10-18       Impact factor: 2.681

7.  Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia.

Authors:  Anneli Uusküla; Mart Kals; Liina Kosenkranius; Louise-Anne McNutt; Jack DeHovitz J
Journal:  BMC Infect Dis       Date:  2010-03-11       Impact factor: 3.090

8.  Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.

Authors:  Lili Ding; Lea E Widdice; Jessica A Kahn
Journal:  Vaccine       Date:  2017-11-21       Impact factor: 3.641

9.  Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.

Authors:  Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein
Journal:  Clin Infect Dis       Date:  2016-09-20       Impact factor: 9.079

10.  Attitudes surrounding implementation of the HPV vaccine for males among primary care providers serving large minority populations.

Authors:  Abraham Aragones; Denise Bruno; Francesca Gany
Journal:  J Health Care Poor Underserved       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.